Literature DB >> 22692508

Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.

Crystina L Kriss1, Javier A Pinilla-Ibarz, Adam W Mailloux, John J Powers, Chih-Hang Anthony Tang, Chang Won Kang, Nicola Zanesi, Pearlie K Epling-Burnette, Eduardo M Sotomayor, Carlo M Croce, Juan R Del Valle, Chih-Chi Andrew Hu.   

Abstract

Chronic lymphocytic leukemia (CLL) represents 30% of adult leukemia. TCL1 is expressed in ~ 90% of human CLL. Transgenic expression of TCL1 in murine B cells (Eμ-TCL1) results in mouse CLL. Here we show for the first time that the previously unexplored endoplasmic reticulum (ER) stress response is aberrantly activated in Eμ-TCL1 mouse and human CLL. This includes activation of the IRE-1/XBP-1 pathway and the transcriptionally up-regulated expression of Derlin-1, Derlin-2, BiP, GRP94, and PDI. TCL1 associates with the XBP-1 transcription factor, and causes the dysregulated expression of the transcription factors, Pax5, IRF4, and Blimp-1, and of the activation-induced cytidine deaminase. In addition, TCL1-overexpressing CLL cells manufacture a distinctly different BCR, as we detected increased expression of membrane-bound IgM and altered N-linked glycosylation of Igα and Igβ, which account for the hyperactive BCR in malignant CLL. To demonstrate that the ER stress-response pathway is a novel molecular target for the treatment of CLL, we blocked the IRE-1/XBP-1 pathway using a novel inhibitor, and observed apoptosis and significantly stalled growth of CLL cells in vitro and in mice. These studies reveal an important role of TCL1 in activating the ER stress response in support for malignant progression of CLL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22692508      PMCID: PMC3680046          DOI: 10.1182/blood-2011-11-394346

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.

Authors:  George F Widhopf; Craig J Goldberg; Traci L Toy; Laura Z Rassenti; William G Wierda; John C Byrd; Michael J Keating; John G Gribben; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2007-08-03       Impact factor: 22.113

Review 2.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

3.  A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.

Authors:  Maria Chiara Di Bernardo; Dalemari Crowther-Swanepoel; Peter Broderick; Emily Webb; Gabrielle Sellick; Ruth Wild; Kate Sullivan; Jayaram Vijayakrishnan; Yufei Wang; Alan M Pittman; Nicola J Sunter; Andrew G Hall; Martin J S Dyer; Estella Matutes; Claire Dearden; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; Peter Hillmen; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; James M Allan; Daniel Catovsky; Richard S Houlston
Journal:  Nat Genet       Date:  2008-08-31       Impact factor: 38.330

Review 4.  Toll-like receptors: lessons to learn from normal and malignant human B cells.

Authors:  David Chiron; Isabelle Bekeredjian-Ding; Catherine Pellat-Deceunynck; Régis Bataille; Gaëtan Jego
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

5.  Identification of the TCL1 gene involved in T-cell malignancies.

Authors:  L Virgilio; M G Narducci; M Isobe; L G Billips; M D Cooper; C M Croce; G Russo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

6.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

7.  XBP-1-deficient plasmablasts show normal protein folding but altered glycosylation and lipid synthesis.

Authors:  Annette M McGehee; Stephanie K Dougan; Elizabeth J Klemm; Guanghou Shui; Boyoun Park; You-Me Kim; Nicki Watson; Markus R Wenk; Hidde L Ploegh; Chih-Chi Andrew Hu
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

8.  Derlin-1 is overexpressed on the tumor cell surface and enables antibody-mediated tumor targeting therapy.

Authors:  Yuliang Ran; Hai Hu; Dong Hu; Zhuan Zhou; Yuemin Sun; Long Yu; Lixin Sun; Jian Pan; Jun Liu; Tong Liu; Zhihua Yang
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

9.  PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

Authors:  Claudia Holler; Josefina D Piñón; Ursula Denk; Christoph Heyder; Sebastian Hofbauer; Richard Greil; Alexander Egle
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113

10.  XBP-1 regulates signal transduction, transcription factors and bone marrow colonization in B cells.

Authors:  Chih-Chi Andrew Hu; Stephanie K Dougan; Annette M McGehee; J Christopher Love; Hidde L Ploegh
Journal:  EMBO J       Date:  2009-04-30       Impact factor: 11.598

View more
  33 in total

Review 1.  When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.

Authors:  Huining Su; Mimi Wang; Xingchen Pang; Feng Guan; Xiang Li; Ying Cheng
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 2.  Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

Authors:  Ying Huang; Jia-Zhu Wu; Jian-Yong Li; Wei Xu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

3.  Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.

Authors:  Chih-Hang Tang; Shiun Chang; Ayumi Hashimoto; Yi-Ju Chen; Chang Won Kang; Anthony R Mato; Juan R Del Valle; Dmitry I Gabrilovich; Chih-Chi Hu
Journal:  Cancer Immunol Res       Date:  2018-04-12       Impact factor: 11.151

4.  Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.

Authors:  Harvey E Johnston; Matthew J Carter; Kerry L Cox; Melanie Dunscombe; Antigoni Manousopoulou; Paul A Townsend; Spiros D Garbis; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2017-01-04       Impact factor: 5.911

5.  Inhibition of the hexosamine biosynthesis pathway potentiates cisplatin cytotoxicity by decreasing BiP expression in non-small-cell lung cancer cells.

Authors:  Wenshu Chen; Kieu C Do; Bryanna Saxton; Shuguang Leng; Piotr Filipczak; Mathewos Tessema; Steven A Belinsky; Yong Lin
Journal:  Mol Carcinog       Date:  2019-03-06       Impact factor: 4.784

6.  Structural Tailoring of a Novel Fluorescent IRE-1 RNase Inhibitor to Precisely Control Its Activity.

Authors:  Andong Shao; Chang Won Kang; Chih-Hang Anthony Tang; Christopher F Cain; Qin Xu; Claire M Phoumyvong; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  J Med Chem       Date:  2019-05-22       Impact factor: 7.446

Review 7.  The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.

Authors:  Yuri Pekarsky; Alessandra Drusco; Prasanthi Kumchala; Carlo M Croce; Nicola Zanesi
Journal:  Gene Expr       Date:  2015

8.  Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.

Authors:  Chih-Hang Anthony Tang; Sujeewa Ranatunga; Crystina L Kriss; Christopher L Cubitt; Jianguo Tao; Javier A Pinilla-Ibarz; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

9.  Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells.

Authors:  Chih-Hang Anthony Tang; Joseph A Zundell; Sujeewa Ranatunga; Cindy Lin; Yulia Nefedova; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  Cancer Res       Date:  2016-03-07       Impact factor: 12.701

10.  Development of Tumor-Targeting IRE-1 Inhibitors for B-cell Cancer Therapy.

Authors:  Andong Shao; Qin Xu; Walker T Spalek; Christopher F Cain; Chang Won Kang; Chih-Hang Anthony Tang; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  Mol Cancer Ther       Date:  2020-10-13       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.